Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time
Despite being the very first molecular targeted agents registered for the treatment of advanced kidney cancer (in the post-cytokines setting), Sorafenib seemed to lose its momentum as a credible first-line treatment option, when it proved not to be superior to Interferon within a randomized phase II...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2011-09-01
|
| Series: | Oncology Reviews |
| Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/10 |
| Summary: | Despite being the very first molecular targeted agents registered for the treatment of advanced kidney cancer (in the post-cytokines setting), Sorafenib seemed to lose its momentum as a credible first-line treatment option, when it proved not to be superior to Interferon within a randomized phase II trial... |
|---|---|
| ISSN: | 1970-5557 1970-5565 |